-0.095 (-5.053%)
ASX:Live
Short Term
Mean Reversion
Very Weak
Trend
Very Strong
Event
Neutral
Halo Model
MQV
Very Weak
GARP
Very Weak
MQV Small
Very Weak
Valuation
Value
Consensus
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Strong
Telephone
61.3.9545.5940
Address
700 Swanston Street Level 7 Carlton, Victoria (VIC) 3053
Description
4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. It develops pipeline products that may assist physicians to more effectively diagnose and manage patients with lung disease, which includes XV ventilation analysis, ventilation perfusion, contrast free pulmonary angiography, small animal ventilator, and preclinical scanner. The company was founded by Andreas Fouras in December 2012 and is headquartered in Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.22 - 2.38
Trade Value (12mth)
AU$527,802.00
1 week
6.82%
1 month
226.96%
YTD
291.67%
1 year
358.54%
All time high
2.98
EPS 3 yr Growth
67.70%
EBITDA Margin
-731.80%
Operating Cashflow
-$34m
Free Cash Flow Return
-48.40%
ROIC
-42.20%
Interest Coverage
-167.90
Quick Ratio
0.80
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Technology
Next Company Report Date
27-Aug-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.01
| Date | Announcements |
|---|---|
|
17 September 25 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
|
17 September 25 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
|
16 September 25 |
Investor Webinar - Dr Kyle Hogarth
×
Investor Webinar - Dr Kyle Hogarth |
|
12 September 25 |
Supplementary announcement - 4DX agreements
×
Supplementary announcement - 4DX agreements |
|
12 September 25 |
Updated Top 20 Option Holders & Distribution Schedule
×
Updated Top 20 Option Holders & Distribution Schedule |
|
11 September 25 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
|
11 September 25 |
Notification regarding unquoted securities - 4DX
×
Notification regarding unquoted securities - 4DX |
|
11 September 25 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
|
11 September 25 |
Top 20 Option Holders & Distribution Schedule
×
Top 20 Option Holders & Distribution Schedule |
|
09 September 25 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
|
09 September 25 |
Notification regarding unquoted securities - 4DX
×
Notification regarding unquoted securities - 4DX |
|
09 September 25 |
Notification regarding unquoted securities - 4DX
×
Notification regarding unquoted securities - 4DX |
|
09 September 25 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
|
09 September 25 |
Cleansing Notice
×
Cleansing Notice |
|
08 September 25 |
4DX signs agreements with national lung screening sites
×
4DX signs agreements with national lung screening sites |
|
05 September 25 |
S&P DJI Announces September 2025 Quarterly Rebalance
×
S&P DJI Announces September 2025 Quarterly Rebalance |
|
04 September 25 |
Notification of Date of 2025 AGM
×
Notification of Date of 2025 AGM |
|
04 September 25 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
|
04 September 25 |
Notification regarding unquoted securities - 4DX
×
Notification regarding unquoted securities - 4DX |
|
03 September 25 |
4DMedical gains U.S. CMS reimbursement for CTVQ
×
4DMedical gains U.S. CMS reimbursement for CTVQ |
|
03 September 25 |
Notification of upcoming expiry of Listed Options
×
Notification of upcoming expiry of Listed Options |
|
02 September 25 |
4DMedical receives $6.0m R&D Tax Incentive
×
4DMedical receives $6.0m R&D Tax Incentive |
|
01 September 25 |
4DMedical receives FDA clearance for CTVQ
×
4DMedical receives FDA clearance for CTVQ |
|
29 August 25 |
Appendix 4E - Preliminary Final Report
×
Appendix 4E - Preliminary Final Report |
|
29 August 25 |
FY2025 Full year results
×
FY2025 Full year results |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
